Full Text View
Tabular View
No Study Results Posted
Related Studies
Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP)
This study is currently recruiting participants.
Study NCT00622726   Information provided by The University of Texas Health Science Center, Houston
First Received: February 13, 2008   Last Updated: November 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Retinopathy of Prematurity
Additional conditions recognized in this trial
Retinal Diseases
More general conditions related to this trial
Eye Diseases
Infant, Newborn, Diseases
Infant, Premature, Diseases
Interventions listed in this trial
Bevacizumab
Conventional Laser for ROP
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
The University of Texas Health Science Center, Houston


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services